The maximum tolerated dose was not reached, and the recommended phase 2 dose was established as oral decitabine 35 mg plus cedazuridine 100 mg for 5 days and venetoclax (400 mg) for 14 days. The most ...

The results of this study mirror those of a similar phase III trial in patients with chemotherapy-naïve extensive-stage small-cell lung cancer (SCLC; ClinicalTrials.gov identifier: NCT01450761) 34 in ...

A confirmatory phase 3 trial of lurbinectedin in patients with relapsed SCLC is ongoing (LAGOON; NCT05153239) after ATLANTIS, a phase 3 trial in relapsed SCLC with lurbinectedin plus doxorubicin, did ...

MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data ...

RESULTS from an international Phase III clinical trial presented at the 2025 ASCO Annual Meeting evaluate a treatment regimen combining encorafenib and cetuximab with mFOLFOX6 chemotherapy in patients ...

The XT GT debuted in March 1968 as a refinement of the XR GT that preceded it. The GT was distinguished by GT driving lights, black rear panel, new full-width grille, rectangular indicators mounted ...

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

Otsuka has shared positive data from its Phase III VISIONARY clinical trial (NCT05248646) of sibeprenlimab in adults with immunoglobulin A nephropathy (IgAN). The investigational monoclonal antibody ...

Low-Cost Domestic Titanium for Defense Applications: Receipt of an SBIR Phase III Indefinite Delivery, Indefinite Quantity (IDIQ) contract to achieve “Low-Cost Domestic Titanium for Defense ...

Objectives While very early mobilisation (VEM) intervention for stroke patients was shown not to be effective at 3 months, 12 month clinical and economical outcomes remain unknown. The aim was to ...